CONGRESS '19

EAHM

BELGIUM - GHENT



THANKS TO OUR SPONSORS





























INNOVATIVE HEALTHCARE STRATEGIES

SIMULTANEOUS TRANSLATION

- 1. NL
- 2. FR
- 3. DUI
- 4. ENG



WiFi

Network: Meetdistrict-Guest

Password: meetdistrict



Mr. Danny Havenith

Congress chair

Official welcoming by the congress chair



INNOVATIVE HEALTHCARE STRATEGIES

Prof. Dr. Eric Mortier CEO Ghent University Hospital Welcoming speech







INNOVATIVE HEALTHCARE STRATEGIES

E.P. MORTIER





WHY DO WE NEED INNOVATION IN HEALTHCARE?





CONTEXT

Demography Economics





CONTENT

Molecular and Synthetic Biology Big Data, Data Mining and Risk Prediction Artificial Intelligence





INNOVATIVE HEALTHCARE STRATEGIES

Dr. Paul Stoffels Vice Chairman & CSO Johnson & Johnson Keynote speech





Advancing Health Through Science & Technology Innovation

Paul Stoffels, M.D.,

Vice Chairman, Executive Committee Chief Scientific Officer

Johnson Johnson

Creating value through innovation for more than 130 years

Diversified across 3 sectors:



Consumer



Medical Devices



Pharmaceutical

Over

250 operating companies

Over

130,000 employees worldwide

Johnson-Johnson



\$10.8B

Invested in R&D in 2018

26

platforms addressing major unmet needs

Deep scientific expertise

Fueling healthcare ecosystem

Long-standing commitment in global public health

Partner of choice


16



Innovation has changed the trajectory of healthcare

From life expectancy of 47 in 1900	•	60% increase in life expectancy
HIV diagnosis – two years to live, high pill burden	•	Near normal life expectancy with HIV, treat with one pill, once-a-day
Toxic oncology treatments	•	Targeted therapies and personalized solutions
Surgeon-targeted device innovation	•	Robotics and digital surgery
Inhumane treatments & institutionalization in mental health	•	Long acting treatments

Scientific advances have redefined the treatment paradigm for many serious diseases in the past two decades





We are experiencing the next wave of scientific & technological breakthroughs


- Quantity and quality of actionable human biology is expanding exponentially
- Technological breakthroughs
 permit new platforms and modalities
 to act on this biology

- Large data sets and machine learning/
 Al are driving disruption across all
 aspects of discovery and development
- Extreme collaboration across stakeholders & geographies

Opportunity to uniquely impact future of health

Addressing Major Healthcare Challenges with Significant Global Burden

Cancer	Heart Disease
HIV	Tuberculosis
Diabetes	Ebola & other pandemics
Alzheimer's Disease	Safe surgery



Harnessing today's science & technology

Select examples



Cell Therapy & CAR-T

Robotic Surgery

Data/Al

Prevention, Early Intervention


Cell therapy has the potential to change the practice of medicine

Deliver curative cell therapies that transform unmet medical need in oncology

Advance current autologous clinical programs rapidly through POC and into registrational studies

Enhance manufacturing capabilities and noveloperational and logistical approaches

Develop next generation cell therapies to address limitations of autologous products



- Phase 1/2a manufacturing unit operational
- Commercial manufacturing site under construction
- EU manufacturing site under evaluation



- Improved safety profile
- Robust, persistent curative response
- Efficient, effective clinical evaluation
- Large-scale, cost-effective manufacturing

Near-term focus

Autologous cell therapies in hematologic malignancies


Long-term focus

Allogeneic cell therapies in hematologic malignancies and solid tumors

JNJ-4528: Potential best-in-class BCMA CAR-T cell therapy



Binding domain(s)



- JNJ-4528 has two binding domains for BCMA
 - Potential to be best-in-class
- LEGEND-2 first-in-human Phase 1/2 study completed enrollment in China with LCAR-B38M;
 74 patients treated^{1,2}
 - Longer follow-up data expected this year
- CARTITUDE-1 Phase 1b/2 study in R/R multiple myeloma ongoing in US
 - Initial data expected end of 2019 or 1H 2020
- CARTIFAN-1 Phase 2 study in R/R multiple myeloma ongoing in China


^{1.} Fan F, et al. J Clin Oncol 2017;35(suppl): abstract LBA3001


^{2.} Zhao WH, et al. 2018. ASH Annual Meeting; abstract 955 (oral presentation)

Revolutionizing surgery to deliver better outcomes



J&J digital surgery innovation ecosystem





Impact of AI and data on transforming the healthcare sector

New technologies

- Cloud computing
- · Wireless communications
- Mobile devices
- · Big data analytics
- · Al & machine learning



Enabling knowledge & decision-making

- · Health informatics
- Bioengineering
- · Virtual assistants
- · Computer-aided diagnosis
- · Clinical decision support
- Wearable systems & health apps



Revolutionizing healthcare

- · From big data to smart data
- From HCP driven to patient-driven
- From episodic to continuous care
 Early detection, diagnosis, treatment, outcome prediction
- From clinic-centered to anywhere the patient is located

The Heartline™ Study is a heart health research study from Johnson & Johnson, in collaboration with Apple













Envisioning a world without disease

PREVENT, INTERCEPT and CURE disease


INTERCEPT
Arrest disease development while still incubating

CURE
Eliminate disease and restore health

HIV vaccine: key to achieving a world without HIV







Intercepting, diagnosing & treating lung cancer

Healthy Incubating **Early Stage Lung Cancer Late Stage Lung Cancer TODAY'S PATIENT JOURNEY CHALLENGES** 70% patients Early-stage lung cancer is Lack of early diagnosis Limited non-invasive access diagnosed late difficult to treat and eradicate 18% 5-yr survival rate MONARCH ENDOBRONCHIAL SOLUTIONS Intercept **Locate & Diagnose Treat** Local delivery targeting Early detection accessing peripheral All-in-one procedure to access and lung lesions treat early-stage lung cancer pre-malignancies **Double the 5-yr** survival rate **Oncolytic Virus Horizon 3** Horizon 1 **Horizon 2**

What I learned along the way

Key ingredients for long-term success



A vision for where you want to go



A focus on meeting unmet needs & delivering value



Risk-taking



Collaboration









"There is so much more to be done... the patients are waiting"

- Dr. Paul Janssen



Delivering value through transformational innovation



We transformed our organization with a focus on transforming lives

Up to 2009

- 6 R&D organizations
- 7 Therapeutic areas
- Wide footprint
- Multiple pre-clinical and clinical operations, regulatory, medical safety organizations
- **Duplication of platforms** and technologies
- Internally focused

After 2009

- One Janssen team
- 6 Therapeutic Area Teams: end to end
- Innovation: internal and external
- New platforms
- Excellence in global execution
- Creating value for patients, society and our business

Key Principles

- Expertise
- Focus
- End-to-end accountability
- Empowered leaders at all levels


















Note: Logos representational and not inclusive of all entities.





The Pharmaceutical Companies of Johnson & Johnson



\$8.4B

Invested in R&D in 2018

Remarkable record of delivering



18 New medicines since 2011

Includes all clinically-relevant articles (original articles, reviews, and editorials, but not supplements and correspondence) published to-date in NEJM, JAMA, Lancet, Science, and Nature since 2014





Deep scientific expertise



30 total Priority Review designations



10 total Breakthrough Therapy and PRIME designations

Clinical/scientific community recognition in last 5 years3

38 NEJM/Lancet/ JAMA

Science/ **Nature**

Tapping into the explosion of scientific opportunities and entrepreneurship in ecosystem

7MM+

Scientific/medical publications in last 5 years¹

> \$57B

Biotech venture capital investment in last 5 years²

4,300+

Companies participating in pharmaceutical R&D³

8,500+

Licensing and collaborative R&D deals in last 5 years⁴

Only 6% of the active pipeline in the industry originated by top 10 Pharma companies³

- 1. Scopus Search, Copyright © 2019 Elsevier B.V. All rights reserved. Scopus is a registered trademark of Elsevier B.V.
- 2. Vantage PharmaMedtech 2018 Review (Evaluate Pharma Feb 2019)
- 3. Pharma R&D Annual Review 2019 (Pharma Intelligence Mar 2019)
- 4. IQVIA pharma deals review of 2018 (IQVIA Mar 2019)

Johnson Johnson

Advancing our innovation agenda through collaboration

Artificial intelligence



a JLABS company using AI to detect signs of Alzheimer's in speech patterns.

Big data



collaboration; using big data to create a blood test to detect early stage cancers.

Treating dry eye



Acquired first FDA-cleared treatment for leading cause of Dry Eye

3D printing



Collaboration on 3D printing patient-specific bioresorbable implants for trauma patients

Microbiome



collaboration with a JLABS company; rebalancing the skin's microbiome to treat acne & other skin conditions

Robotic surgery



a collaboration with Google's life sciences arm to develop a robot-assisted surgery platform using machine learning and VR/AR

CAR-T



Collaboration on CAR-T Cell Immunotherapy targeting Multiple Myeloma

Gene therapy



Gene therapy for treating inherited retinal diseases

Treating IBD



Collaboration to develop oral JAK inhibitor for inflammatory intestinal diseases

Johnson Johnson

Identifying and Advancing the Best Science

Engagement with innovators spanning consumer, health tech, medical devices, vision care, pharmaceutical & cross-sector









INNOVATION CENTERS

Early Stage Acceleration

Full Deal Teams

- 4 Innovation Centers in life science hotspots on 3 Continents
- Broad networks across region connecting innovation ecosystems into the central IC hub to create flexible collaborations
- 400+ deals done over the past six years
- >\$1B deployed since 2013

JJDC

Strategic Investors

Johnson & Johnson Corporate Venture Arm

- 45+years of strategic healthcare investing
- Partnership w/ Innovation Centers to form new companies on rise
- \$450M in 2018

JLABS

Life Science Incubators

- 13 locations across the globe, including 2 JPODS in North America
- 480+ Portfolio Companies
- 120+ collaborations w/ Johnson & Johnson


BUSINESS DEVELOPMENT

Late Stage Deals

- Supports mid- and late-stage deals from any source
- Business Development teams in Janssen, Johnson & Johnson Medical Devices and Johnson & Johnson Consumer
- Licensing, M&A Expertise and Alliance Management
- Janssen Business Development (JBD) works with established biotech and pharma companies at all stages of development; 40+ years leading licensing and M&A deals driving R&D portfolio

Johnson Johnson

Building an innovation network across the globe



Striving to impact health on a global scale

Advancing and enabling access to transformational innovation in developing countries

Tackling some of the biggest health threats in resource-limited settings

- HIV
- Drug-resistant TB
- Mental health
- Soil-transmitted helminths
- Pathogens of global concern:
 - Ebola, Zika, Dengue, Polio

130mm+
Lives impacted





Top 3 Ranking for ~10 Years²

Medicines in the WHO's Essential Medicines list¹





^{1.} Essential medicines and health products. Accessed May 2019. Available at https://...

^{2.} Access to Medicine Index. November 2018. Available at https://accesstomedicinefoundation.org/access-to-medicine-index/report-cards/johnson-johnson

Harnessing scientific innovation for the health of everyone, everywhere



Johnson-Johnson

Thank you!

Prof. Dr. Eugene Fidelis Soh

CEO TTSH and Central Health, Chairman CHI Co- Learning Network

Keynote speech: Transformative shifts in Healthcare.SG



Mr. Pedro Facon Director of Belgian Ministry of Health Welcoming



Mr. Philippe Blua President of the EAHM Official inauguration congress



Miyoko Shida Rigolo. Sanddorn Balance Balance act



Mr. Danny Havenith Congress chairman Praticals









FRIDAY

7:30AM > 8:00PM

WWW.EAHM2019.EU







GHENT CITY CENTRE POI



9:30AM - Pillows Grand Hotel Reylof Hoogstraat 36 · · · · H6

OUTSIDE CITY CENTRE

STATION (TRAM 1)

Gent-Sint-Pieters on 2,5 km from the city centre

MEET & GREET CENTER - MEETDISTRICT

Ghelamco Arena - Ottergemsesteenweg Zuid 808 on +- 6 km from the city centre From Sint Pieters Station > Bus 65 or 67.

V-TAXI +32 (0)9 222 22 22

THANK YOU FOR YOUR ATTENTION

THANKS TO OUR SPONSORS



























